SYRS — Syros Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$17.19m
- $9.94m
U.S. STOCKS ON THE MOVE-BioCryst, gold miners, ChemoCentryx
Syros jumps on European 'orphan drug' tag for blood disorder therapy
TYME Technologies jumps after premium buyout offer from Syros Pharma
Brief: Syros To Raise Approximately $190 Mln Through Merger With Tyme Technologies And Concurrent Private Placement
U.S. RESEARCH ROUNDUP-Helmerich and Payne, J B Hunt Transport Services, Stratasys
Syros Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Syros Pharmaceuticals Reports Q1 Loss Per Share $0.40
Syros Pharmaceuticals Inc expected to post a loss of 47 cents a share - Earnings Preview
Syros Pharmaceuticals Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Syros Reports Fourth Quarter And Full Year 2021 Financial Results
Brief: Syros Pharmaceuticals - On March 7, Entered Into Master Collaboration Agreement And Project Schedule With Qiagen Manchester Limited
Brief: Syros Receives FDA Orphan Drug Designation For Tamibarotene For The Treatment Of Mds
Brief: Syros Announces Clinical Updates And 2022 Goals To Support Its Advancement To A Fully Integrated Biopharmaceutical Company
Syros Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Syros Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Syros Pharmaceuticals Announces Appointment Of Jason Haas As Chief Financial Officer
Brief: Syros Announces First Patient In Dose Confirmation Study Of SY-2101 In Acute Promyelocytic Leukemia
Brief: Syros Appoints Conley Chee As Chief Commercial Officer
Brief: Syros Presents New Data From Phase 1 Trial Of Sy-5609